12.62
                                            Schlusskurs vom Vortag:
              $12.78
            Offen:
              $12.61
            24-Stunden-Volumen:
                72,010
            Relative Volume:
              0.06
            Marktkapitalisierung:
                $969.38M
            Einnahmen:
              $54.55M
            Nettoeinkommen (Verlust:
              $-193.57M
            KGV:
              -4.3678
            EPS:
                -2.89
            Netto-Cashflow:
                $-181.86M
            1W Leistung:
              +14.11%
            1M Leistung:
              +36.96%
            6M Leistung:
                +9.76%
            1J Leistung:
              -48.52%
            Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
                  
                      Nurix Therapeutics Inc
                    
                Sektor
                  Branche
                  Telefon
                  
                      (415) 660-5320
                    
                Adresse
                  
                      1700 OWENS STREET, SUITE 205, SAN FRANCISCO
                    
                Vergleichen Sie NRIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV | 
|---|---|---|---|---|---|---|
|   
                          
                                NRIX
                            
                             Nurix Therapeutics Inc | 12.68 | 1.30B | 54.55M | -193.57M | -181.86M | -2.89 | 
|   
                          
                                VRTX
                            
                             Vertex Pharmaceuticals Inc | 419.32 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 | 
|   
                          
                                REGN
                            
                             Regeneron Pharmaceuticals Inc | 650.66 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 | 
|   
                          
                                ALNY
                            
                             Alnylam Pharmaceuticals Inc | 442.86 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 | 
|   
                          
                                ARGX
                            
                             Argen X Se Adr | 815.13 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 | 
|   
                          
                                INSM
                            
                             Insmed Inc | 191.63 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 | 
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung | 
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Mizuho | Outperform | 
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform | 
| 2024-12-10 | Eingeleitet | BTIG Research | Buy | 
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform | 
| 2024-10-24 | Eingeleitet | UBS | Buy | 
| 2024-10-11 | Eingeleitet | Jefferies | Buy | 
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform | 
| 2024-07-31 | Eingeleitet | Truist | Buy | 
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform | 
| 2023-03-09 | Eingeleitet | Barclays | Overweight | 
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform | 
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight | 
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight | 
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight | 
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy | 
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform | 
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform | 
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight | 
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform | 
| 2021-04-14 | Eingeleitet | Berenberg | Buy | 
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform | 
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight | 
| 2020-08-18 | Eingeleitet | Needham | Buy | 
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight | 
| 2020-08-18 | Eingeleitet | Stifel | Buy | 
                    Alle ansehen
                     
                  
                Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
How institutional ownership impacts Nurix Therapeutics Inc. stock2025 Momentum Check & Safe Capital Preservation Plans - newser.com
Full technical analysis of Nurix Therapeutics Inc. stockJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com
How moving averages guide Nurix Therapeutics Inc. tradingMarket Performance Report & Daily Risk Controlled Trade Plans - newser.com
Will Nurix Therapeutics Inc. stock go up soonPortfolio Value Summary & Consistent Profit Trading Strategies - newser.com
Nurix Therapeutics CFO van Houte sells $40k in shares By Investing.com - Investing.com UK
Will Nurix Therapeutics Inc. stock deliver consistent dividendsQuarterly Trade Review & Risk Controlled Daily Plans - newser.com
Can Nurix Therapeutics Inc. recover in the next quarterEarnings Summary Report & Daily Momentum Trading Reports - newser.com
Nurix Therapeutics CLO ring sells shares for $46,631 By Investing.com - Investing.com Canada
Nurix therapeutics CSO Hansen sells $52k in shares By Investing.com - Investing.com Philippines
Nurix Therapeutics CFO van Houte sells $40k in shares - Investing.com
Nurix therapeutics CSO Hansen sells $52k in shares - Investing.com
Nurix Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Nurix Therapeutics (Nasdaq: NRIX) to join Stifel Nov 13 and Jefferies Nov 19 webcasts - Stock Titan
Is Nurix Therapeutics Inc. building a consolidation baseInflation Watch & High Return Trade Guides - newser.com
HC Wainwright Cuts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $28.00 - MarketBeat
Visual trend scoring systems applied to Nurix Therapeutics Inc.July 2025 Retail & Technical Confirmation Trade Alerts - newser.com
AlphaQuest LLC Boosts Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics Inc. stock daily chart insightsJuly 2025 Gainers & Technical Entry and Exit Tips - newser.com
What technical charts say about Nurix Therapeutics Inc. stockTrade Risk Report & Low Risk High Reward Ideas - newser.com
Nurix Therapeutics (NASDAQ:NRIX) Trading 7.7% HigherHere's Why - MarketBeat
HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
Nurix stock price target lowered to $28 at H.C. Wainwright on trial updates - Investing.com UK
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 34% Price Boost Is Out Of Tune With Revenues - 富途牛牛
Will Nurix Therapeutics Inc. bounce back from current supportWeekly Risk Summary & AI Optimized Trading Strategy Guides - newser.com
Applying chart zones and confluence areas to Nurix Therapeutics Inc.Weekly Trade Report & Long-Term Growth Stock Strategies - newser.com
Nurix Therapeutics closes $250 million stock offering By Investing.com - Investing.com Philippines
Why Nurix Therapeutics Inc. stock is seen as undervaluedQuarterly Trade Review & Safe Swing Trade Setup Alerts - Fundação Cultural do Pará
Nurix Therapeutics’ NX-1607 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Nurix Therapeutics Advances NX-5948 Study in B-cell Malignancies - TipRanks
Nurix Therapeutics’ NX-2127 Study: A Potential Game-Changer in B-cell Malignancy Treatment - TipRanks
Nurix Therapeutics’ NX-5948 Study: A Potential Game-Changer in Drug Delivery - TipRanks
Fenwick Represents Nurix Therapeutics in its $250M Registered Common Stock Offering - fenwick.com
Nurix Therapeutics closes $250 million stock offering - Investing.com
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock - Investing News Network
Nurix (NASDAQ: NRIX) closes 24.5M-share offering at $10.21 for CLL, autoimmune - Stock Titan
Leerink Partnrs Has Bullish Outlook for NRIX FY2025 Earnings - MarketBeat
Can Nurix Therapeutics Inc. stock hit record highs againJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nurix Therapeutics Inc-Aktie (NRIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt | 
|---|---|---|---|---|---|---|---|
| van Houte Hans | Chief Financial Officer | Oct 30 '25 | Sale | 12.80 | 3,130 | 40,054 | 43,876 | 
| Ring Christine | Chief Legal Officer | Oct 30 '25 | Option Exercise | 0.00 | 10,532 | 0 | 54,541 | 
| Ring Christine | Chief Legal Officer | Oct 30 '25 | Sale | 12.80 | 3,644 | 46,631 | 50,897 | 
| Hansen Gwenn | Chief Scientific Officer | Oct 30 '25 | Option Exercise | 0.00 | 11,815 | 0 | 80,838 | 
| Hansen Gwenn | Chief Scientific Officer | Oct 30 '25 | Sale | 12.80 | 4,087 | 52,300 | 76,751 | 
| GREGORY JULIA P | Director | Sep 17 '25 | Option Exercise | 1.86 | 10,750 | 19,995 | 10,750 | 
| van Houte Hans | Chief Financial Officer | Aug 01 '25 | Sale | 11.03 | 5,402 | 59,598 | 35,512 | 
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):
                 
            
         
                     
                             Holen Sie sich die Stockscreener-App
                    Holen Sie sich die Stockscreener-App